Top Qs
Timeline
Chat
Perspective
Center for Genetic Engineering and Biotechnology
State-owned biotechnology institute in Cuba From Wikipedia, the free encyclopedia
Remove ads
The Center for Genetic Engineering and Biotechnology (Spanish: Centro de Ingeniería Genética y Biotecnología, CIGB) is a research institute in Havana, Cuba.
Remove ads
Remove ads
Founding
In 1982, the United Nations Industrial Development Organization (UNIDO) offered grant funding via a competitive application process to facilitate biotechnology development in the Third World.[1]: 132 Cuba sought, but did not receive funding, which instead was awarded to a joint project proposed by India and Italy.[1]: 132 Cuba nonetheless proceeded with the development of a biotechnology research institution using its own funds, CIGB.[1]: 132
Remove ads
Activity
In 2006, CIGB developed the Heberprot-P, which is used to treat foot ulcers.[2] Its use results in rapid wound healing and a 75% decrease in amputations among diabetics with foot ulcers.[2]
As of 2017, CIGB had 1,600 employees and sold 21 products internationally.[1]: 138
As of 2020, CIGB had two joint ventures with China.[1]: 143
It is responsible for creating the Abdala vaccine.[3][4][5]
The Centre developed the COVID-19 vaccine Mambisa, which is in the final stages of clinical trials.[6]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads